Physician profile
Isha Gupta
NPI 1255598744
$1,816.00
in general payments reported to CMS, 2019-2025
29 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.76 · 2020: $223 · 2021: $89.16 · 2022: $142 · 2023: $159 · 2024: $506 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $258.07 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $180.70 | 2020-2024 | Freestyle Libre 3, Proclaim, Eterna |
| Pfizer INC. | $171.66 | 2019-2025 | |
| Abbvie INC. | $129.71 | 2020-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $123.93 | 2020 | |
| Corcept Therapeutics | $117.28 | 2024-2025 | Korlym |
| Lundbeck LLC | $98.52 | 2024 | Rexulti |
| Lilly USA, LLC | $88.73 | 2024-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.81 | 2021-2025 | Jardiance, Synjardy |
| Amgen INC. | $67.91 | 2024-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $51.77 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $51.19 | 2024-2025 | Gemtesa |
| Inspire Medical Systems, INC. | $50.61 | 2023-2025 | Inspire |
| Dexcom, INC. | $49.70 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $38.98 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25.46 | 2025 | Wavewriter Alpha Prime 16 |
| Ge Healthcare | $23.99 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.42 | 2023 | Rebyota |
| Daiichi Sankyo INC. | $19.55 | 2019 | |
| Nevro Corp. | $18.60 | 2023 | Senza |
| Sunovion Pharmaceuticals INC. | $18.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.31 | 2024 | Rexulti |
| Medtronic USA, INC. | $16.65 | 2020 | |
| Philips North America LLC | $16.44 | 2020 | |
| Sanofi Pasteur INC. | $16.16 | 2019 | |
| Allergan, INC. | $15.62 | 2020 | |
| Neurocrine Biosciences, INC. | $15.54 | 2024 | |
| Abiomed | $14.35 | 2023 | Impella |
| Astrazeneca Pharmaceuticals Lp | $13.94 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isha Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.